Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Notices - 2001 > Denial of Petition

Notices - 2001


Institute of Medicine (1982). Division of Health Sciences Policy. Marijuana and Health:
           Report of a study by committee of the Institute of Medicine, Washington, D.C. National Academy Press. Institute of Medicine (1999). Marijuana and medicine: Assessing the science base. Washington, D.C.: National Academy Press.
Isbell H, Gorodetzky CW, Jasinski D, Claussen U, VonSpulak F, & Korte F (1967). Effects
           of (-)-9-tetrahydrocannabinol in man. Psychopharmacologia 11:184-188. 
Izquierdo I, Tannhauser M (1973). Letter: The effect of cannabidiol on maximal
           electroshock seizures in rats. J Pharm Pharmacol 25:916- 917.
Jarbe TU, Hiltunen AJ, & Mechoulam R (1989). Subjectively experienced cannabis effects
           in animals. Drug Develop Res 16:385- 393.
Jarbe TU, & Hendricksson BG (1974). Discriminative response control produced by
           hashish, tetrahydrocannabinols ( 8-THC and 9-THC) and other drugs. Psychopharmacologia (Berl.) 40:1- 16.
Jarbe TU, Hendricksson BG, & Ohlin GC (1977). 9-THC as a discriminative cue in 
           pigeon: effects of 8-THC, CBD, and CBN. Arch Internat Pharmacodyn Ther 228:68-72.
[[Page 20074]]

Jarbe TU, & Mathis DA (1992). Dissociative and discriminative stimulus functions of
           cannabinoids/cannabimimetics. In: Murphy L & Bartke A (Eds), Marijuana/Cannabinoids: Neurobiology and Neurophysiology. CRC Press, Boca Raton, FL, pp. 425-458.
Johnston LD, O'Malley PM, & Bachman JG (1996). National Survey Results on Drug
           Abuse from the Monitoring the Future Study, 1975- 1995. Volume 1: Secondary School Students. U.S. Government Printing Office: Washington, DC. 
Jones RT (1971). Marijuana-induced "high": influence of expectation, setting and previous
           drug experience. Pharmacol Rev 23:359-369.
Jones RT (1980). Human effects: an overview. In: Petersen RC (Ed) Marijuana research
           findings: 1980. NIDA Res Mono 31. U.S. Govt Printing Office: Washington DC, pp 54-79.
Jones RT, Benowitz NL, & Herning RI (1981). Clinical relevance of cannabis tolerance 
           and dependence. J Clin Pharmacol 21:143S-152S.
Jones RT, Pertwee RG (1972). A metabolic interaction in vivo between cannabidio and
           delta-1-tetrahydrocannabinol. Br J Pharmacol 45:375- 377.
Kamien JB, Bickel WK, Higgins ST, & Hughes JR (1994). The effects of
           9-tetrahydrocannabinol on repeated acquisition and performance of response sequences and on self-reports in humans. Behav Pharmacol 5:71-78.
Karniol IG, & Carlini EA (1972). The content of (-) 9-trans-tetrahydrocannabinol (9-THC)
           does not explain all biological activity of some Brazilian marijuana samples. J Pharm Pharmacol 24:833-835. 
Karniol IG, & Carlini EA (1973). Comparative studies in man and in laboratory animals on
           8-and 9-trans-tetrahydrocannabinol. Pharmacology 9:115-126.
Karniol IG, & Carlini EA (1973). Pharmacological interaction between cannabidiol and
           9-tetrahydrocannabinol. Psychopharmacologia (Berl) 33:53-70. 
Karniol IG, Shirakawa I, Kasinski N, Pfefferman A, & Carlini EA (1974). Cannabidiol
           interferes with the effects of 9- tetrahydrocannabinol in man. Eur J Pharmacol 28:172-178.
Kaymakcalan S (1973).Tolerance and dependence on cannabis. Bull Narc 25:39-47.
Kelly P, & Jones RT (1992). Metabolism of tetrahydrocannabinol in frequent and 
           infrequent marijuana users. J Anal Toxicol 16:328-335. 
Kelly TH, Foltin RW, Emurian CS, Fischman MW (1997). Are choice and
           self-administration of marijuana related to delta-9-THC content? Exp Clin Psychopharmacol 5:74-82. Kelly TH, Foltin RW, & Fischman MW (1993). Effects of smoked marijuana on heart rate, drug ratings and task performance by humans. Behav Pharmacol 4:167-178.
Kelly TH, Foltin RW, Mayr MT, & Fischman MW (1994). Effects of 9-tetrahydrocannabinol
           and social context on marijuana self-administration by humans. Pharmacol Biochem Behav 49:763-768. 
Kessler R, McGonagle K, Zhao S, Nelson, CB, Hughes M, Eshleman S, Wittchen H-U,
           Kendler KS (1994). Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8-19. 
Kiplinger GF, Manno JE, Rodda BE, Fornery RB, Haine SE, East R, Richards AB (1971).
           Dose-response analysis of the effects of tetrahydrocannabinol in man. Clin Pharmacol Ther 12:650-657. 
Koob GF (1992). Neural mechanisms of drug reinforcement. Ann NY Acad Sci
 Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, Merlo-Pich E,
           Weiss F (1998). Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 22:3-9. 
Khouri EM, Pope HG, Lukas SE (1999). Changes in aggressive behavior during
           withdrawal from long-term marijuana use. Psychopharmacology 143:302-308.
Kouri EM, Pope HG (2000) Abstinence symptoms during withdrawal from chronic
           marijuana use. Exper Clin Psychopharmacol 8: 483-492. 
Kurzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Gunther V, Wechdorn H, Battista
           H-J, Fleischhacker WW (1999). Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry 60:395-399. Lemberger L, Crabtree R, Rowe HM (1972). 11-hydroxy-9-tetrahydrocannabinol: pharmcology, disposition, and metabolism of a major metabolite of marihuana in man. Science 177:62-64. 
Lemberger L, & Rubin A. (1975). The physiologic disposition of marijuana in man. Life 
           Sci 17:1637-1642. 
Lepore M, Vorel SR, Lowinson J, Gardner EL (1995). Conditioned place preference
           induced by 9-tetrahydrocannabinol: Comparison with cocaine, morphine and food reward. Life Sci 56:2073-2080.
Lichtman A, & Martin BR (1996). 9-tetrahydrocannabinol impairs spatial memory through 
           a cannabinoid receptor mechanism. Psychopharmacology 126:125-131.
Little PJ, Compton DR, Johnson MR, Melvin LS, & Martin BR (1988). Pharmacology and
           stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exper Ther 247:1046.
Lukas SE, Mendelson JH, Benedikt R (1995). Electroencephalographic correlates of
           marihuana-induced euphoria. Drug Alcohol Depend 37:131-140.
Machula IA, Dudkin SM, & Barkov NK (1992). Characterization of mechanisms mediating
           the effects of 9-tetrahydrocannabinol on behavior. In: Murphy L & Bartke A (Eds), Marijuana/Cannabinoids. Neurobiology and Neurophysiology. CRC Press, Boca Raton, FL; pp. 525-538.
Manno JE, Kiplinger GF, Scholz N, Forney RB, Haine SE (1971). The influence of alcohol
           and marihuana on motor and mental performance. Clin Pharmacol Ther 12:202-211.
Manno JE, Kiplinger GF, Haine SE, Bennett IF, Forney RB (1970). Comparative effects of
           smoking marihuana on placebo on human motor and mental performance. Clin Pharmacol Ther 11:808-815.
Martin BR, Balster RL, Razdan RK, Harris LS, & Dewey WL (1981). Behavioral
           comparisons of stereoisomers of tetrahydrocannabinols. Life Sci 29:565.
Martin BR, Compton DR, Prescott WR, Barrett RL, & Razdan RK (1995).
           Pharmacological evaluation of dimethylheptyl analogs of 9- THC: reassessment of the putative three-point cannabinoid-receptor interaction. Drug Alcohol Depend 37:231-240. 
Martin BR, Hall W (1997, 1998). The health effects of cannabis: key issues of policy
           relevance. Bulletin on Narcotics XLIX & L (1&2):85- 116.
Martin G, Nie Z, Siggens GR (1997). Mu-Opioid receptors modulate NMDA
           receptor-mediated responses in nucleus accumbens neurons J Neurosci 17:11-22.
Mechoulam R (1973). Marijuana: Chemistry, pharmacology, metabolism, and clinical
           effects. NY: Academic Press. 
Mechoulam R (1998). Endocannabinoids. Eur J Pharmacol 359:1-18.
Mechoulum R, Shani A, Edery HM, & Grunfield Y (1970). Chemical basis for hashish
           activity. Science 169:611-612. 
Mello NK (1989). Drug self-administration procedures: Alcohol and marijuana. In:
           Fischman MW, & Mello NR (Eds). Testing for Abuse Liability of Drugs in Humans. US Government Printing Office:, Washington, DC; pp.147-170.
Mello NK, & Mendelson JH (1985). Operant acquisition of marijuana by women. J
           Pharmacol Exper Therap 235:162-171. 
Mendelson JH, & Mello NK (1984). Reinforcing properties of oral 9-tetrahydrocannabinol,
           smoked marijuana and nabilone: Influence of previous marijuana use. Psychopharmacology 83:351-356.
Mendelson JH, & Mello NK (1984). Effects of marijuana on neuroendocrine hormones in
           human males and females. In Braude, M.C. and Ludford, J.P., (Eds). Marijuana Effects on the Endocrine and Reproductive Systems. National Institute on Drug Abuse Monograph 44. DHHS Pub No. (ADM) 84-1278. U.S. Printing Office: Washington, DC. 
Mendelson JH, Rossi AM, & Meyer RE (1974). The Use of Marijuana: A Psychological 
           and Physiological Inquiry. Plenum Press: New York. Microgram. 30: 1, 1997.
Miller LL, Cocchetto DM, & Perez-Reyes M (1983). Relationship between several
           pharmacokinetic parameters and psychometric indices of subjective effects of 9-tetrahydrocannabinol in man. Eur J Pharmacol 25:633-637. 
Monti JM (1977). Hypnotic-like effects of cannabidiol in the rat. Psychopharmacology
Musty RE (1984). Possible anxiolytic effects of cannabidiol. In: Agurell S, Dewey WL,
           Willette RE (Eds) The cannabinoids: chemical, pharmacologic, and
therapeutic aspects. NY: Academic Press, pp. 795-815.
[[Page 20075]]

Musty RE, & Sands R (1978). Effects of marijuana extract distillate and cannabidiol on
           variable interval performance as a function of food deprivation. Pharmacology 16:199-205
Musty RE, Reggio P, & Consroe P (1995). A review of recent advances in cannabinoid
           research and the 1994 International Symposium on Cannabis and the Cannabinoids. Life Sci 56:1933-1940. 
Nakamura EM, da Silva EA, Concilio GM, Wilkinson DA, & Masur J (1991). Reversible
           effects of acute and long-term administration of tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 28:167-175. 
National Highway Traffic Safety Administration (2000a). Marijuana and alcohol combined
           severely impede driving performance. Ann Emerg Med 35:398-399. 
National Highway Traffic Safety Administration (2000b). NHTSA Technical Report #225.
National Highway Traffic Safety Administration (1999). NHTSA Technical Report #201.
National Highway Traffic Safety Administration (1998). NHTSA Technical Report #185.
National Institute in Drug Abuse (1996). Conference Highlights. National Conference on Marijuana Use: Prevention, Treatment, and Research.
           July 19-20, 1995. Sponsored by National Institute in Drug Abuse, National Institutes of Health, NIH Publication No, 96:96-4106. 
NCADI: 1996 DAWN Survey.
Nelson K, Walsh D, Deeter P, & Sheehan F (1994). A Phase II study of
           delta-9-tetrahydrocannabinol for appetite stimulation in cancer- associated anorexia. J Palliat Care 10:14-18.
Nemeth-Coslett R, Henningfield JE, O'Keefe MK, & Griffiths RR (1986). Effects of
           marijuana smoking on suvjective ratings of tobacco smothing. Pharmacol Biochem Behav 25:569-665. 
Nilsson I, Agurell S, Nilsson JLG, Widman M, Leander K (1973). Two cannabidiol
           metabolites formed by rat liver. J Pharm Pharmacol 25: 486-487.
Onaivi ES, Green MR, Martin BR (1990). Pharmacological characterization of
           cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253: 1002-1009.
Paris M, Nahas GG (1984). Botany: the unstabilized species. In: Nahas GG (Ed.)
           Marihuana in science and medicine. NY: Raven Press, pp 3-36.
Paris M, Boucher F, & Cosson L (1975). Importance des compose a chaine propylique
           dans le Cannabis originaire d'Afrique du Sud. Plantes Med Phytother 9:136-139.
Parker LA, & Gillies T (1995). THC-induced place and taste aversions in Lewis and
           Sprague-Dawley rats. Behav Neurosci 109:71-78. 
Patton WDM, & Pertwee RG. (1973). The actions of cannabis in man. In: Mechoulam R
           (Ed), Marijuana: chemistry, pharmacology, metabolism, and clinical effects. Academic Press: New York, pp 287- 333. 
Perez-Reyes M, Simmons J, Brine D, Kimmel GL, Davis KH, Wall ME (1976). Rate of
           penetration of delta-9-tetrahydrocannabinol and 11- hydroxy-delta-9-tetrahydrocannabinol to the brain of mice. In: Nahas G, Paton WDM, Idanpaan-Heikkila JE (Eds), Marihuana: chemistry, biochemistry, and cellular effects. Springer-Verlag: New York, pp 179-185.
Perez-Reyes M, Timmons MC, Davis KH, & Wall EM (1973). A comparison of the
           pharmacological activity in man of intravenously administered delta-9-tetrahydrocannabinol, cannabinol, and cannabidiol. Experientia 29:1368-1369.
Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Cook CE (1991). The
           pharmacologic effects of daily marijuana smoking in humans. Phamacol Biochem Behav 40: 691-694. 
Perio A, Rinaldi-Carmona M, Maruani J, Barth F, LeFur G, & Soubrie P (1996). Central
           mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65-71.
Pertwee RG (1991) Tolerance to and dependence on psychotropic cannabinoids. In: The
           Biological Bases of Drug Tolerance and Dependence. Academic press: New York; pp. 231-263. 
Phillips RN, Turk RF, & Forney RB (1971). Acute toxicity of delta-9- tetrahydrocannabinol
           in rats and mice. Proc Soc Exper Biol Med 136:260.
Physicians Desk Reference, 51st edition. (1997). Medical Economics Company, Inc.,
           Monvale, New Jersey, pp. 2353-2355.
Pickens R, Thompson T, & Muchow DC (1973). Cannabis and phencyclidine
           self-administered by animals. In:Goldfarb L, & Hoffmeister F (Eds) Psychic Dependence (Bayer-Symposium IV). Springer-Verlag, Berlin; pp. 78.
Pope HG, & Yurgelun-Todd D (1996). The residual cognitive effects of heavy marijuana
           use in college students. JAMA 275:521-527. Pradhan SN (1984). Pharmacology of some synthetic tetrahydrocannabinols. Neurosci Biobehav Rev 8:369-385. 
Preston KL, Walsh SL, & Sannerud CA (1997). Indirect measures related to drug
           reinforcement. In: Johnson BA, & Roache J (Eds), Drug Addiction and its Treatment: Nexus of Neuroscience and Behavior. Raven Press:New York; pp 91-114. 
Razdan RK (1986). Structrue-activity relationships in cannabinoids. Pharmacol Rev 
Razdan RK, & Howes JF (1983). Drugs related to tetrahydrocannabinol. Med Res Rev
Report to the Director, National Institutes of Health, by the Ad Hoc Group of Experts,
           (1997). Workshop on the Medical Utility of Marijuana, National Institutes of Health, Bethesda, MD February 19- 20, 1997, available on the NIH Homepage Date: July 25, 1997.
Sanders J, Jackson DM, & Starmer GA (1979). Interactions among the cannabinoids in
           the antagonism of the abdominal constriction response in the mouse. Psychopharmacology 61:281-285. 
Sarafian TA, Marques-Magallanes JA, Shau H, Tashkin D, Roth MD (1999). Oxidative
           stress produced by marijuana smoke: an adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol 20: 1286- 1293.
Substance Abuse and Mental Health Services Administration (1999). Federal study links
            wide range of behavior problems to marijuana use by teens. A SAMHSA report: adolescent self-reported behaviors and their association with marijuana use. http://www.samhsa.gov/press/980922fs.htm
Takahashi RN, & Singer G (1979). Self-administration of 9- tetrahydrocannabinol by rats.
           Pharmacol Biochem Behav 11:737.
Tanda G, Munzar P, Goldberg SR (2000). Self-administration behavior maintained by the
           psychoactive ingredient of marijuana in squirrel monkeys. Nature Neurosci 3: 1073-1074.
Tart CT (1971). On Being Stoned: A Psychological Study of Marijuana Intoxication.
           Science and Behavior Books: Palo Alto, CA.
Taylor DR, Poulton R, Moffitt TE, Ramankutty P, Sears MR (2000). The respiratory effects
           of cannabis dependence in young adults. Addiction 95:1669-1677.
Ten Ham M, & DeJong Y (1975). Absence of interaction between 9-tetrahydrocannabinol
           9-THC) and cannabidiol in aggression, muscle control, and body temperature experiments in mice. Psychopharmacologia (Berl) 41:169-174.
Thomas BF, Adams IB, Mascarella SW, Martin BR, & Razdan RK (1996). Structure
           -activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J Med Chem 39:471-479. 
Thompson GW, et al. (1970-1972). Determine toxicity of delta-8 and
           delta-9-tetrahydrocannabinol and marijuana extract. Mason Research Institute, Worcester, Massachusetts Reports I-XIX to the National Institutes of Mental Health. Contract No. HSM 42-70-95 (June 1970- June 1971) and No. HSM 42-71-79 (June 1971-January 1972).
Tsou K, Patrick SL, & Walker JM (1995). Physical withdrawal in rats tolerant to
           9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13-R15.
Turner CE (1980). Chemistry and metabolism. In: Petersen RC (Ed) Marijuana research
           findings: 1980. NIDA Res Mono 31. U.S. Gov't Printing Office: Washington DC, pp 81-97.
Turner CE (1980). Marijuana research and problems: an overview. Pharmac Internat
           May: 93-96. 
Turner CE, ElSohly MA, & Boeren EG (1980a). Constituents of cannabis sativa
           L. XVII. A review of the natural constituents. J Nat Prod 43:169- 234.
[[Page 20076]]

Turner CE, Elsohly MA, Boeren EG (1980b). Constituents of Cannabis sativa. XV.
           Botanical and chemical profile of Indian variant. Planta Med 37:217-225.
Turner CE, Elsohly MA, Lewis GS, Lopez-Santibanez I, Carranza J (1982). Constituents
           of Cannabis sative L., XX: the cannabinoid content of Mexican variants grown in Mexico and in Mississippi, United States of America. Bull Narc 34:45-59.
Turner JC, Hemphill JK, Mahlberg PG (1980). Trichomes and cannabinoid content of
           developing leaves and bracts of Cannabis sativa L., Cannabacceae. Am J Bot 67:1397-1406. 
U.S. Department of Justice. Drug Enforcement Administration (1994). Cannabis
           Investigations Section. 1993 Domestic cannabis Eradication/ Suppression Program. Washington, DC. U.N. Division of Narcotic Drugs (1974). The chemistry of cannabis and its components. MNAR/9/1974-GE, 74-11502.
U.N. International Narcotics Control Board (1994). Psychotropic Substances, Statistics for
           1993. United Nations Publication, Vienna, Austria, pp. 39-42.
U.S. Department of Health and Human Services (1995). National Household Survey on
           Drug Abuse. Main Findings, 1993, U.S. Government Printing Office, Washington, DC 1995.
U.S. Department of Health and Human Services (1995). National Household Survey on
           Drug Abuse. Population Estimates 1994, U.S. Government Printing Office, Washington, DC.
Vachon L, Sulkowski A, & Rich E. (1974). Marihuana effects on learning, attention and
           time estimation. Psychopharmacology 39:1-11.
Wall ME, Perez-Reyes M (1981). The metabolism of delta-9- tetrahydrocannabinol and
           related cannabinoids in man. J Clin Pharmacol 21:178S-189S.
Welburn PJ, Starmer GA, Chesher GB, & Jackson DM (1976). Effets of cannbinoids on
           the abdominal constriction response in mice: within cannbinoid interactions. Psychopharmacologia (Berl.) 46:83-85. 
Weil AT, & Zinberg NE (1969). Acute effects of marihuana on speech. Nature
Weil AT, Zinberg NE, & Nelsen JM (1968). Clinical and psychological effects of 
           marihuana in man. Science 162:1231-1242. 
Wiley JL, Barrett RL, Balster RL, & Martin BR (1993a). Tolerance to the discriminative
           stimulus effects of 9-tetrahydrocannabinol. Behav Pharmacol 4:581-585.
Wiley JL, Barrett RL, Britt DT, Balster RL, & Martin BR (1993b). Discriminative stimulus
           effects of 9- tetrahydrocannabinol and 9-11- tetrahydrocannabinol in rats and rhesus monkeys. Neuropharmacology 32:359-365.
Wiley JL, Huffman JW, Balster RL, & Martin BR (1995a). Pharmacological specificity of
           the discriminative stimulus effects of 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend 40:81-86.
Wiley JL, Lowe JA, Balster RL, & Martin BR (1995b). Antagonism of the discriminative
           stimulus effects of 9- tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exper Therap 275:1-6.
Wise RA (1996). Neurobiology of addiction. Curr Opin Neurobiol 6:243-251.
Wise RA, Bozarth MA (1987). A psychomotor stimulant theory of addiction. Psychol Rev
Wu X, French ED (2000). Effects of chronic 9- tetrahydrocannabinol on rat midbrain
           dopamine neurons: an electrophysiological assessment. Neruopharmacology 39:391-398.
Yesavage A, Leirer VO, Denari M, Hollister LE (1985). Carry-over effects of marijuana
           intoxication on aircraft pilot performance: A preliminary report. Am J Psychiatry 142:1325-1329.
Yuan XR, Madamba S, Siggens GR (1992). Opioid peptides reduce synaptic
           transmission in the nucleus accumbens. Neurosci Lett 134:223-228.
Zacny JP, Chait LD (1989). Breathhold duration and response to marijuana smoke.
           Pharmacol Biochem Behav 33:481-484. 
Zacny JP, Chait LD (1991). Response to marijuana as a function of potency and
           breathhold duration. Psychopharmacology 103:223-226.
Zhang Z-F, Morgenstern H, Spitz MR, Tashkin DP, Yu G-P, Marshall R,  Hsu TC, Schantz
           SP (1999). Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers & Prevent 8:1071-1078. 
Zuardi AW, Antunes Rodriguez J, & Cunha JM (1991). Effects of cannabidiol in animal
           models predictive of antipsychotic activity. Psychopharmacology 104:260-264.
Zuardi AW, & Karniol IG (1983). Effect on variable-interval performance in rats of
           "9-tetrahydrocannabinol and cannabidiol, separately and in combination. Brazil J Med Biol Res 16:141-146.
Zuardi AW, Finkelfarb E, Bueno OFA, Musty RE, & Karniol IG (1981). Characteristics of
           the stimulus produced by the mixture of cannabidiol with 9-tetrahydrocannabinol. Arch Internat Pharmacodynam Ther 249:137-146.
Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995). Antipsychotic effect of
           cannabidiol. J Clin Psychiatry 56:485-486. 
Zuardi AW, Shirakawa I, Finkelfarb E, & Karniol IG (1982). Action of cannabidiol on the
           anxiety and other effects produced by 9- THC in normal subjects. Psychopharmacology 76:245-250. 
Zuardi AW, Teixeira NA, & Karniol IG (1984). Pharmacological inter action of the effects 
           of 9-trans-tetrahydrocannabinol and cannabidiol on serum corticisterone levels in the rat. Arch Internat Pharmacodyn Ther 269:12-19.

[FR Doc. 01-9306 Filed 4-17-01; 8:45 am]


Previous Page

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility